JNJ logo
Johnson & Johnson
JNJ
258.45 (0.06%) 0.15
Market cap
$622.84(B)
Earnings date
Oct-13-2026
Category
Sector
Health Care
Industry
Pharmaceuticals
Johnson & Johnson together with its subsidiaries engages in the research and development manufacture and sale of a range of products in the healthcare field worldwide. It operates in two segments Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas such as oncology immunology neuroscience pulmonary hypertension infectious diseases and cardiovascular and metabolism distributed through retailers wholesalers distributors hospitals and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery orthopedic cardiovascular and vision fields distributed through wholesalers hospitals and retailers and used in the professional fields by physicians nurses hospitals eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction trauma spine sports related injuries and others as well as open laparoscopic and robotic surgical procedures; instrumentation energy devices stapling systems wound closure biosurgery products and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick New Jersey.
EV: $678.43(B)
Total Equity: $84.97(B)
Debt/Equity: 0.58
Dividend/share: $5.2
Div. yield: 2.03%
P/E: 29.57
Forward P/E: 23.35
P/FCF: 27.97
P/S: 6.35
P/B: 7.33
EPS: $8.7
EPS (fwd): $11.1
FCF/share: $9.2
Revenue/share: $40.7
Book value/share: $35.3
ROIC: 21.7%
ROA: 13.5%
ROE: 33.6%
Margins: Gross | Op. | Net
68.1% | 26.2% | 21.5%
0.0%of Portfolio
My holdings
Day change
Total change

JNJ Valuation & Price Targets

Favorite Valuation Methods

PEvaluation
—
Analyst targets
—
DCF (2-stage)
—

More Valuation Methods

DCF (simple)
—
DCF (exit mult.)
—
DDM
—
EPS growth
—
Revenue growth
—
Peter Lynch FV
—
Graham No.
—

PEvaluation

CURRENT PRICE
$258
8% Overvalued
BEAR
BASE
BULL
Fair P/E
Margin of safety
EPS
Market Model
ROICRevenue growthFCF MarginShares outstan...Debt/EquityDebt/EBITDA
Economic moat: Wide

EPS Estimates

LowAvgHigh#
FY+111.011.111.26
FY+211.312.113.55
FY+312.514.215.54
FY+413.816.618.13
FY+515.318.921.03

Analyst Price Targets

CURRENT PRICE
$258
9% Undervalued
BEAR
BASE
BULL

Analyst Recommendations

Strong Buy5
Buy11
Hold6
Sell1
Strong Sell0

2-stage DCF

First Stage Duration: 5 Years
Starting Free Cash Flow
First Stage Growth Rate
Low
Mid
High
Terminal Growth Rate
Low
Mid
High
Discount Rate

Discounted Cash Flow

Forecast years: 5 Years
Terminal Growth Rate
Low
Mid
High
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Discounted Cash Flow (exit mult.)

Forecast years: 5 Years
Exit FCF Multiple
Low
Mid
High
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Dividend Discount Model

Annual Dividend
First Stage Length (Years): 0 Years
First Stage Growth Rate
Low
Mid
High
Final Growth Rate
Low
Mid
High
Discount Rate

EPS Growth

Forecast years: 5 Years
Starting EPS
EPS Growth Rate
Low
Mid
High
Final P/E
Low
Mid
High
Discount Rate

Revenue Growth Valuation

Forecast Years: 10 Years
Base Revenue
Revenue Growth Rate
Low
Mid
High
Final Net Margin
Low
Mid
High
Final P/E Ratio
Low
Mid
High
Discount Rate

Peter Lynch Fair Value

Earnings Per Share
Growth Rate
Low
Mid
High

Graham Formula

Earnings Per Share
EPS Growth (7-10 years)
Low
Mid
High
Government Bond Rate